Literature DB >> 31760592

Effects of cabergoline therapy on serum IGF-1 concentrations in prolactinoma patients.

Pedro Iglesias1,2, Carles Villabona3, Juan J Díez4,5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31760592     DOI： 10.1007/s11102-019-01011-4

Source DB:  PubMed          Journal:  Pituitary        ISSN： 1386-341X            Impact factor:   4.107


× No keyword cloud information.
  9 in total

1.  Complete remission of macroprolactinoma after long-term medical therapy with dopamine agonists.

Authors:  P Iglesias; J J Díez
Journal:  QJM       Date:  2010-07-27

2.  Cabergoline in the treatment of acromegaly: a study in 64 patients.

Authors:  R Abs; J Verhelst; D Maiter; K Van Acker; F Nobels; J L Coolens; C Mahler; A Beckers
Journal:  J Clin Endocrinol Metab       Date:  1998-02       Impact factor: 5.958

Review 3.  Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline.

Authors:  Shlomo Melmed; Felipe F Casanueva; Andrew R Hoffman; David L Kleinberg; Victor M Montori; Janet A Schlechte; John A H Wass
Journal:  J Clin Endocrinol Metab       Date:  2011-02       Impact factor: 5.958

4.  Biochemical acromegaly in patients with prolactinoma during treatment with dopaminergic agonists.

Authors:  Pedro W Rosário; Saulo Purisch
Journal:  Arq Bras Endocrinol Metabol       Date:  2010-08

5.  Acromegaly: an endocrine society clinical practice guideline.

Authors:  Laurence Katznelson; Edward R Laws; Shlomo Melmed; Mark E Molitch; Mohammad Hassan Murad; Andrea Utz; John A H Wass
Journal:  J Clin Endocrinol Metab       Date:  2014-10-30       Impact factor: 5.958

Review 6.  Place of cabergoline in acromegaly: a meta-analysis.

Authors:  Laure Sandret; Patrick Maison; Philippe Chanson
Journal:  J Clin Endocrinol Metab       Date:  2011-02-16       Impact factor: 5.958

7.  IGF-1 levels may increase paradoxically with dopamine agonist treatment for prolactinomas.

Authors:  Amit Akirov; Yona Greenman; Benjamin Glaser; Irena S'chigol; Yossi Mansiterski; Yoav Eizenberg; Ilana Shraga-Slutzky; Ilan Shimon
Journal:  Pituitary       Date:  2018-08       Impact factor: 4.107

8.  Development of acromegaly in patients with prolactinomas.

Authors:  Marianne Andersen; Casper Hagen; Jan Frystyk; Henrik Daa Schroeder; Claus Hagen
Journal:  Eur J Endocrinol       Date:  2003-07       Impact factor: 6.664

9.  Late presentation of acromegaly in medically controlled prolactinoma patients.

Authors:  Ekaterina Manuylova; Laura M Calvi; Catherine Hastings; G Edward Vates; Mahlon D Johnson; William T Cave; Ismat Shafiq
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2016-10-17
  9 in total
  1 in total

1.  Long-term IGF-1 monitoring in prolactinoma patients treated with cabergoline might not be indicated.

Authors:  Lukas Andereggen; Janine Frey; Emanuel Christ
Journal:  Endocrine       Date:  2020-12-04       Impact factor: 3.633
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.